Table 1.

Clinical Characteristics of the 48 Patients with Concomitant EGFR Mutations and HER2 Amplification Lung Cancer

Characteristic	Patients
Age, years, median (range)	56.5 (39–84)
Sex, n (%)
Male	21 (43.8%)
Female	27 (56.2%)
Histology, n (%)
Adenocarcinoma	45 (93.7%)
Adenocarcinoma with mixed SCLC	1 (2.1%)
Large cell neuroendocrine carcinoma	1 (2.1%)
Unknown	1 (2.1%)
Prior chemotherapy, n (%)
Yes	12 (25%)
No	33 (68.8%)
Unknown	3 (6.2%)
EGFR-TKI resistance, n (%)
Resistance to 1st/2nd generation	27 (56.2%)
Resistance to 3rd generation	21 (43.8%)
Treatment lines, n (%)
Post-1st/2nd line treatment	31 (64.6%)
Post-3rd/3rd line post-treatment	17 (35.4%)
Sample type for NGS, n (%)
Tumor tissue	20 (41.7%)
ctDNA	28 (58.3%)